Discovering and developing novel therapeutics targeting GPCR heteromers in cancer
Every Hope Matters
The incorporation of GPCR Therapeutics USA, INC. We are proud to announce that the Secretary of State of the State of California certified the incorporation of GPCR Therapeutics USA, INC. on April 7, 2021. GPCR Therapeutics is currently searching for laboratory space in the San Francisco Bay area and has plans to expand and grow our U.S. site. The focus of the site will be both Research and Development in Oncology. The most advanced clinical candidate is Burixafor, which is planned to initiate a clinical trial in the US next year, to prove our CXCR4 heteromer hypothesis. Additionally, we will be utilizing our technologies to identify key GPCR heteromers as therapeutics targets in Oncology. Dr. Pina Cardarelli will be heading up the team of talented researchers that will be expanding in the coming years.
